Artelo (ARTL) Short-Term Debt to Equity

Graphic logo of Artelo Biosciences (ARTL)

Artelo Biosciences focuses its business on developing cannabinoid receptor modulators to treat chronic pain and cancer-related anorexia. This chart illustrates the asset's price action, while the individual debt-to-equity ratio stands at 0.01. Growth for Artelo Biosciences is driven by successful Phase II trials of the ART27.13 drug, the development of neuropathy therapies, and the strengthening of intellectual property rights within the lipid sector.

ARTL - artelobio.com Short-Term Debt to Equity Ratio over the range 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for Artelo (ARTL)

- stock quotes and analyst forecast:
Stock Price Artelo Biosciences|ARTL - Analyst Consensus Forecast
- market capitalization details:
Market Value Artelo Biosciences Inc.|ARTL - Value Adjusted for Debt and Cash
- balance sheet equity data:
Book Value per Share Artelo Biosciences|ARTL - Company Net Assets|Market Value to Book Value Ratio artelobio.com|ARTL - Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Artelo Biosciences|ARTL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Artelo Biosciences|ARTL - Company Aggregate Indebtedness|Debts to Book Capitalization Artelo Biosciences Inc.|ARTL - Company Long-Term Debts|Company Short-Term Debt Artelo Biosciences|Quick Liquidity artelobio.com
- earnings and market ratios statistics:
ARTL - Net Income
Fundamental company valuation:Artelo Biosciences, Inc.
Product sample of Artelo

Due to minimal geopolitical risks in the biopharmaceutical sector, the stability of Artelo Biosciences (ARTL) allows for an assessment of the balance between financial prudence and the efficient use of debt with maturities exceeding one year to cover peak loads via changes in the short-term debt-to-equity ratio on GURU.Markets, which determines the company's ability to scale research without risking a loss of liquidity.

Analysis of competing companies

Short-Term Debt to Capital INDV|Short-Term Debt to Capital Collegium Corp (COLL)|Short-Term Debt to Equity Cronos Group Inc. CRON|Ratio of Short-Term Indebtedness to Capital CGC|High Tide - Short-Term Debt to Capital|Aurora Cannabis (ACB) - Short-Term Debt to Equity Ratio|Achieve Life Sciences, Inc (ACHV) - Short-Term Debt to Equity|Current Liabilities to Capital skyebioscience.com (SKYE)|Short-Term Debt to Equity Ratio ANEB|INCR: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital NTRB|NSRX: Current Liabilities to Equity|Short-Term Debt to Capital IGC (IGC Pharma)|Short-Term Debt to Capital MIRA Pharmaceuticals Inc. MIRA|FLGC - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMCC (IM Cannabis Corp.)|adialpharma.com (ADIL) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Ensysce Biosciences, Inc.|TTNP (Titan Pharmaceuticals Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Greenlane Corp|Short-Term Debt to Equity InMed Pharmaceuticals (INM)|AKAN (akandacorp.com) - Ratio of Short-Term Indebtedness to Capital|Enveric Biosciences, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio BGXX (Bright Green Corp.)|Hempacco - Short-Term Debt to Capital